Full-Time

Key Account Manager - Dry Eye

Harrow

Harrow

201-500 employees

Compounds ophthalmic formulations; markets branded drugs

No salary listed

Jamaica, NY, USA

In Person

70-80% travel with overnights; based in Valley Stream, NY.

Category
Sales & Account Management
Required Skills
Sales
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Bachelor’s degree in a related field
  • Has 1-4 years of pharmaceutical or medical device sales experience (Ophthalmic experience is beneficial)
  • Proficient with MS Office products, including Word, Excel, and PowerPoint
  • Ability to travel throughout the assigned geography on a routine basis (approximately 70-80% travel)
  • Understanding of the Pharmaceutical Industry’s Code of Practice
  • Comply with all state and federal-specific legislation and regulatory requirements
  • Excellent presentation and interpersonal skills
  • Superior communication and written skills
  • Ability to multitask, adjusting priorities as needed
  • Good problem-solving and analytical skills
  • Ability to become proficient with the CRM System
  • Maintain an in-depth and professional level understanding of the ophthalmic product portfolio and competition
  • Articulate clinical benefits of products/formulations and solutions in a compliant manner
  • Strong sense of urgency in customer care and follow-up
  • Ability to build, develop, and foster longstanding relationships with customers
  • Experience in developing quarterly action plans and partnering with accounts
  • Knowledge of payer landscape, Commercial, Medicare Part D, and dual eligibility
  • Knowledge of how physicians make decisions regarding patient care for various therapies
  • Clinical understanding in ophthalmology (preferred)
  • Solid independent judgment and initiative
  • 70% weekly travel in a defined territory with overnights required
  • Bachelor’s degree in a related field
Responsibilities
  • Meet or exceed quarterly sales revenue and product goals
  • Take 100% ownership and accountability to reach the goals set by the company
  • Develop the territory by focusing on new customers and converting the existing customer base
  • Analyze, develop, and grow the territory business with an entrepreneurial mindset
  • Drive demand through organic pull-through and deploy reimbursement solutions
  • Call on ophthalmic healthcare professionals in defined markets
  • Develop critical physician and staff relationships within the assigned geography
  • Utilize internal resources when developing quarterly action plans and partnering with accounts
  • Record all sales activity in CRM in a timely manner
  • Maintain proficiency with PowerPoint, Excel, Word & Outlook
  • Maintain an in-depth and professional level understanding of the ophthalmic product portfolio and the competition
  • Articulate clinical benefits of products/formulations and solutions in a compliant manner
  • Act with a sense of urgency at all levels of customer care and follow up
  • Collaborate with internal departments and peers
  • Travel throughout the assigned geography on a routine basis; travel 75-80% with overnights
  • Understand and comply with Pharmaceutical Industry’s Code of Practice
  • Comply with state and federal-specific legislation and regulatory requirements
  • Manage expenses ethically and responsibly
  • Submit all required reports, including monthly expense reports, on time
Desired Qualifications
  • Ophthalmic sales experience (beneficial)
  • Experience with ophthalmic product portfolio and competition knowledge (beneficial)
  • Ability to absorb product and practice information quickly and offer solutions that resonate (preferred)
  • Clinical understanding in ophthalmology is preferred
  • Knowledge of payer landscape (Commercial, Medicare Part D, dual eligibility) is preferred
  • Experience with CRM System proficiency (preferred)
  • Ability to travel 70-80% weekly travel (preferred)

Harrow focuses on eyecare pharmaceuticals, combining a compounding business (ImprimisRx) with a portfolio of FDA-approved branded drugs and biosimilars, plus biotech investments. Its products include customized compounded sterile and topical eye medications delivered directly to physicians and patients, alongside branded drugs acquired from other companies. The company differentiates itself by integrating a direct-to-physician compounding platform with an expanding branded drug portfolio, biosimilars, and owned production and distribution facilities across all 50 states. Its goal is to provide accessible, high-quality eye medications and grow its commercial and biotech assets to serve surgeons, hospitals, and patients nationwide.

Company Size

201-500

Company Stage

IPO

Headquarters

Nashville, Tennessee

Founded

1998

Your Connections

People at Harrow who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VEVYE prescriptions rose about 25% sequentially in Q1 2026.[1]
  • TRIESENCE unit volume increased 136% year over year in Q1 2026.[1]
  • VERKAZIA's relaunch adds a pediatric, steroid-sparing product with access initiatives.[1]

What critics are saying

  • VEVYE faced an $8 million gross-to-net hit from high-deductible patients in Q1 2026.[1]
  • IHEEZO generated only $1.9 million in Q1 2026 because channel inventory absorbed demand.[1]
  • Higher debt from 2030 notes increases interest burden and reduces financial flexibility.[1]

What makes Harrow unique

  • Harrow sells only eyecare pharmaceuticals, including compounded and branded ophthalmic products.[1][2]
  • Mark Baum founded Harrow in 1998 and still serves as Chairman and CEO.[1]
  • Its portfolio spans ImprimisRx, IHEEZO, VEVYE, TRIESENCE, VERKAZIA, and other ophthalmic brands.[1]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

21%

1 year growth

21%

2 year growth

21%
Simply Wall St
Mar 26th, 2026
How Investors May Respond To Harrow (HROW) Issuing US$50M In 8.625% Senior Notes For Growth

Harrow, Inc. recently completed a private fixed‑income offering of US$50,000,000 in 8.625% senior unsecured notes due 2030, callable and guaranteed by its wholly owned domestic restricted subsidiaries, under Regulation S and Rule 144A. The additional 2030 notes give Harrow more financial flexibility to fund growth initiatives, product development, and future business development opportunities without issuing new equity. We’ll now examine how this US$50,000,000 senior unsecured notes issuance...

Yahoo Finance
Mar 3rd, 2026
Harrow misses Q4 earnings estimate by 34.5% despite revenue beat

Harrow reported fourth-quarter earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.40 per share, representing a 34.46% negative surprise. This compares to earnings of $0.25 per share in the same period last year. The pharmaceutical and drug compounding company posted revenues of $89.09 million for the quarter ended December 2025, slightly exceeding the Zacks Consensus Estimate by 0.33% and up from $66.83 million a year earlier. Over the last four quarters, Harrow has surpassed consensus earnings estimates twice and topped revenue estimates once. Harrow shares have gained 10.6% year-to-date, outperforming the S&P 500's 0.5% gain. However, unfavorable estimate revision trends have resulted in a Zacks Rank of 4 (Sell), suggesting potential near-term underperformance.

The Associated Press
Mar 2nd, 2026
Harrow posts record Q4 revenue of $89.1M, up 33%, guides 2026 revenue to $350M–$365M

Harrow, a North American ophthalmic disease management solutions provider, reported record fourth-quarter revenue of $89.1 million, up 33% year-over-year, and full-year 2025 revenue of $272.3 million, up 36% from 2024. The company posted GAAP net income of $6.6 million in Q4 but a full-year net loss of $5.1 million. Adjusted EBITDA reached $24.2 million in Q4 and $61.9 million for the full year. Harrow generated $43.9 million in operating cash flow for 2025, compared to $22.2 million used in operations in 2024. The company provided 2026 guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA. Harrow plans to double sales teams for key products and expand commercial operations whilst advancing its development pipeline.

Stock Titan
Nov 18th, 2025
Harrow Completes Melt Pharmaceuticals Acquisition

Harrow (Nasdaq: HROW) has completed its acquisition of Melt Pharmaceuticals, adding clinical-stage candidates MELT-210, MELT-300, and MELT-400. MELT-300, a sublingual midazolam and ketamine formulation, showed statistical superiority in Phase 2 and 3 trials. Harrow plans to submit an NDA in H1 2027, targeting approval in H1 2028 and commercial launch in H2 2028. Over 800 U.S. ophthalmic institutions currently use Harrow's MKO Melt product.

TipRanks
Sep 30th, 2025
Harrow Health Secures New $40 Million Credit Facility - TipRanks.com

Harrow Health ( ($HROW) ) just unveiled an update. On September 26, 2025, Harrow, Inc. entered into a New Credit Agreement with Fifth Third Bank for a senior secure...